Renovo Share Discussion Threads

[joeblogg2] 14/6/2011 13:31

Seems all the shares I hold is either waiting for news or are being manipulated :((

[hollerich1] 14/6/2011 13:28

who is manipulating this on the cheap.

[daytraders] 13/6/2011 18:38

I know they sold a few in the 60's, then started buying back more after the news.

[holly_dog] 13/6/2011 15:53

Their average pre feb announcement was in the 20s,can't be lower than 17p IMO

[daytraders] 13/6/2011 13:12

At least 17p back here, but with assets im looking at a return of 21p to 24p myself, money for nothing here imo, what was gartmore buying at ? 16p to 18p ? and they aint sold any yet i dont think.

[cumnor] 13/6/2011 11:12

I just think it is an order being filled by one of the present holders at a set price and the mms are using the impatient Pis as a source of cheap shares to fill it while they can. imo

[holly_dog] 13/6/2011 11:09

Reckon something is up..who's got the cash or the cojonas to buy!

[the_doctor] 13/6/2011 10:52

Kestrel needed 1.49m more to increase to 5%

My expectation would be that after the consultation period (90 days to start June or start July - from a review, I think it's 90 days, not working days), RNVO would/should discuss with Gartmore (given their near 30% holding) to discuss what strategy they'd be happy with.
It would be daft to initiate a new strategy, then see Gartmore buy to 30% and initiate a bid in order to drive some other strategy.

[holly_dog] 13/6/2011 10:33

yes that is why the price has declined and obviously it had to decline as much as this because someone wanted to offload quite a chunk so the buyer rightly sat on his hands until they could get a good price for a higher volume of stock.

But more to the point since last monday 3.5m shares have changed hands (plus at least 820k today) which is after Kestrel released last holding RNS so I think we should find out shortly who has been selling down and potentially who has been buying as that is a reasonable amount of shares to move

[the_doctor] 13/6/2011 10:29

I dont think anyone has suggested it is worthless have they?

But yes, similarly, why would firms want to buy stock in a co unless they feel the share price will rise.
Gartmore must fancy the risk-reward of a rise well above 15p...

[hollerich1] 13/6/2011 10:26

but doc that is the point, why will someone wants to buy something worthless?.

[the_doctor] 13/6/2011 10:23

'800k by 10am'

perhaps just that the share price was lowered to find a price at which the buyer and seller could agree?

[holly_dog] 13/6/2011 10:08

Agreed, will be seeing this through to the bitter end as it is worth 17p so no one is getting anything from me for lower than that, tbh it's more just wanting to be able to buy more and ruing my holding being avg 15p when could have had opportunity to bring that down. I believe like you that a pleasant surprise could come our way

Compelling investment case at these levels and someone is really buying a ton at the moment, 800k by 10am holding RNS has to be coming

[hollerich1] 13/6/2011 09:53

pardon my ignorance guys, but it seems someone is still buying loads of this stuff, i mean they can't be stupid just buying without reason.

[cumnor] 13/6/2011 09:34

Holly, relax. This is Aim and an RNS won't come while you are waiting. Well underpinned imo and could be pleasently surprised as the Prof, notwithstanding the unpredictibality of clinical trials, has already shown us he is very well capable of talking and thinking big and doing mega deals (vs the cash and shire) and that he will no doubt be doing the same now, albeit with much smaller mrkt cap but cash in excess, a listing, big holders interested in the company and valuable IP. let him do what he has to and stop telling the mms you are under pressure. They love this with Aim cos and traditionally mark down shareprices in this knowledge knowing they will pick up a few from nervous PIs, irrespective of the fundementals, especially when news imminent. Pure psychology. They could as easy mark it to 20p on cash and listing but that makes PIs confident and less likely to give shares to them, thus they trend for the LCD they get away with. Most people in now are big holders or lths who can afford to wait the final outcome, even if it only means a few pence profit which in the present market is an achievement. But there could be much more upside imo which is why patience is required and why cash rich companies on Aim have more purchasing power than 6 months or a year ago. dyor

[the_doctor] 13/6/2011 09:29

any idea if the 90 days is working days or any days?

[holly_dog] 13/6/2011 09:19

was in the car checking for the RNS at 7..good to have a bounce today but getting quite impatient. I have tied up quite a bit of personal as well as trading capital in this as thought would have an RNS a week ago so feeling a touch nervous and also frustrated now am maxed out to buy at this price

[hollerich1] 10/6/2011 19:07

the_doctor- they are more about like selling everything, i mean tanking out.

[daytraders] 10/6/2011 19:04

Just a while back, Panmure Gordon Buy 15.25p old target 30.00p new target 22.00p Reiteration, i personally think guaranteed 17p plus 4p to 6p on top for other stuff.

[the_doctor] 10/6/2011 18:41

I guess one reason for a drop could be if RNVO stated that it was to acquire more products with the cash - I dont expect it though, given they've sacked so many staff.

[daytraders] 10/6/2011 18:16

Big buys after close also.

[daytraders] 10/6/2011 18:13

stupid price here now, worth over 17p in cash even after all the below is taking into consideration if they go that route imo, were now at just 25mill market capital, risk free at least 25% upside in just cash alone, at all other stuff in for free.

Renovo expects to have cash and cash equivalents of approximately £33 million at 30 June 2011. The cash amount assumes that at 30 June 2011 all redundancy payments, lease and other closure costs have been settled other than the costs required to complete the ongoing Adaprev and Prevascar trials with appropriate levels of managerial and administrative supervision and support.

[hollerich1] 10/6/2011 16:52

-- Juvidex(R) reported significant improvements in pre-specified secondary endpoints of skin appearance and acceleration of healing in a previously reported proof of concept clinical trial in skin graft donor sites in volunteers. Renovo is in discussions to sell Juvidex

-- RN1005 development has ceased. Renovo will seek to sell this and the other preclinical programmes.

[hollerich1] 10/6/2011 16:51

PREVASCAR

Prevascar (INN: Ilodecakin) is a therapeutic formulation of human recombinant Interleukin 10 (IL-10) and is an important modulator of the inflammatory response. Its mechanism of action differs from Juvista.

Renovo has previously reported statistically significant efficacy data for Prevascar in the reduction of scarring in the skin. A new proof of concept clinical study to evaluate the effects of Prevascar on scarring in volunteers of African Ancestral Group origin using an improved drug product is fully recruited.

This trial compares the efficacy of four doses (5, 25, 100 and 250ng/100l/Lcm of wound margin) of Prevascar and placebo when injected intradermally to wound margins immediately after making a full thickness 1cm skin incision under the arm; the wound margins were injected again one day later. Each volunteer of African origin received four cuts, two under each arm, with matched placebo and Prevascar administrations. 56 subjects were recruited to the trial with two groups of 28 subjects each receiving two doses of Prevascar and placebo. All wounds were excised at one month and sectioned for histological evaluation, including for wound width, area and immunohistochemical markers of inflammatory cells as part of the planned interim analysis. The purpose of this planned interim analysis was to determine if there were any findings which might be predictive of improved scarring as assessed clinically 12 months after surgery. Following excision of all four initial incisional wounds on each volunteer, the excision wound sites were injected with the same doses and dosing regimen of Prevascar or placebo as the initial incisions and will be followed out for clinical assessments of scarring up to and including twelve months following these excisions. The trial should report the final data of these 12 month assessments of scarring by the examining surgeon in H1 2012.

The interim data, reported today, show a statistically significant (p = 0.03) improvement (decrease) of around 12% in wound width as measured histologically, with one of the doses of Prevascar, as compared to placebo. Renovo hopes this translates into a significant improvement in clinical scar appearance when assessed at the 12 month endpoint. There were no differences between Prevascar and placebo for any of the inflammatory markers investigated.

This trial reports final clinical scar appearance data in H1 2012. Renovo will seek to sell the rights to Prevascar